Valeant Pharmaceuticals International Inc. (NYSE: VRX) was compared to Enron in a recent research report from Citron Research, a short-selling firm. On this news, shares sank by over 26%. Since then the company has defended itself and its relationship with Philidor, which was questioned in the report, as well as its accounting practices. However, over the week, shares fell 35% and they are down 23% year to date. Shares of Valeant ended the week at $116.16. The stock has a 52-week trading range of $88.50 to $263.81.
Repros Therapeutics Inc. (NASDAQ: RPRX) had a massive share price drop on Wednesday and Thursday on increased volume. Over the course of the week, the stock fell 29%, and shares are down 46% year to date. The stock closed at $5.19 Friday. The consensus analyst price target is $9.00, and the 52-week trading range is $5.03 to $10.72.
Relypsa Inc. (NASDAQ: RLYP) announced the approval of its drug Veltassa, which helps to treat fatally high levels of potassium in patients with chronic kidney disease or heart problems. However, along with the approval the company must post a warning label that the drug also binds many other oral drugs, which could potentially decrease their absorption properties and reduce their effectiveness. The warning recommends taking the drug and any other oral medication at least six hours apart. Last week, shares fell 40%, and they are down nearly 62% year to date. The stock closed at $13.80 on Friday. The consensus price target is $41.33. The 52-week range is $10.26 to $42.26.
Ocular Therapeutix Inc. (NASDAQ: OCUL) announced top-line efficacy results from a Phase 3 clinical trial to evaluate the safety and efficacy of Dextenza (sustained release dexamethasone). However the Dextenza treatment group did not achieve the primary endpoints for conjunctival redness in this trial. As a result, the markets turned sour on this company and shares were down more than 50% in Friday’s session. Over the course of the week, shares fell 56% and they are down 69% year to date. Shares of Ocular were trading at $7.18 on Friday’s close. The stock has a 52-week trading range of $6.75 to $44.19.
Sponsored: Find a Qualified Financial Advisor:
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.